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Abstract 
Equine mesenchymal stem cells (MSCs) have been isolated from various sources such as: 
peripheral blood, bone marrow, adipose tissue, umbilical cord, placenta, Wharton Jelly. Besides these 
synovial fluid and synovial membrane represents a promising source of mesenchymal stem cells, which can 
be harvested by minimally invasive methods. MSCs from these sources have the potential to self-renew and 
differentiate into multiple lineages such as chondrogenic, adipogenic and osteogenic. The aim of our study 
was to evaluate the growth characteristics of equine synovial liquid stem cells harvested from the 
tarsometatarsal joint during arthroscopic surgery. Samples were collected in a sterile syringe and were 
diluted and centrifuged at 1500rpm for 7 min. The supernatant were removed and the cells were resuspended 
in propagation medium: Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12, Gibco) supplemented with 
10% fetal bovine serum (FBS, Gibco) and 1% antibiotic-antimycotic (Sigma-Aldrich). The medium was 
changed after 3 days. The proliferation ability, cell doubling number, cell doubling time, daily duplication 
rate and clonogenic efficacy was evaluated. Isolated cells exhibited plastic adherence capacity, monolayer 
growth, and fibroblast-like morphology, high growth and clonogenic capacity. Our study demonstrated the 
characteristics of equine synovial fluid derived stem cells, an ideal candidate for veterinary regenerative 
medicine. 




Mesenchymal stem cells (MSCs) are multipotent precursor cells with self-renewal and 
differentiation capacity (Dominici et al. 2006, Pall et al., 2015). MSCs are a promising therapeutic 
tool   in    veterinary    medicine    (Bahamondes    et    al.,    2017)    have    been    isolated    
from different animal species including rodents (Penny et al., 2012), dogs (Guercio et al., 2013, 
Bahamondes et al., 2017), horses (Barberini et al., 2014, Pall et al., 2016) and rabbits (Tan et al., 
2013). According to the International Society for Cellular Therapy published in 2006, human 
MSCs are characterized by plastic adherence capacity, trilineage differentiation capacity and 
expression of surface markers such as CD105, CD90, CD44, CD73, CD79α and are negative for 
the expression of hematopoietic markers CD34, CD45 and CD19, CD14, human leukocyte antigen 
HLA-DR (Dominici et al., 2006). MSCs isolated from animals are not fully characterized. Equine 
mesenchymal stem cells (MSCs) have been isolated from various sources such as: peripheral blood, 
bone marrow, adipose tissue, umbilical cord, placenta, Wharton Jelly (Barberini et al., 2014, 
Tessier et al., 2015, Pall et al., 2016). Besides these synovial fluid and synovial membrane 
represents a promising source of mesenchymal stem cells, which can be harvested by minimally 
invasive methods. The aim of our study was to evaluate the growth characteristics of equine 
synovial liquid stem cells harvested from the tarsometatarsal joint during arthroscopic surgery. 
 
Material and methods 
Samples (n=5) were collected in a sterile syringe during atroscopic surgery. The samples 




7 min. The supernatant were removed and the cells were resuspended in propagation medium: 
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12, Gibco) supplemented with 10% fetal 
bovine serum (FBS, Gibco) and 1% antibiotic-antimycotic (Sigma-Aldrich). Cultures were 
incubated at 37 °C in humidified atmosphere with 5 % CO2. After 72 h, non-adherent cells were 
removed and the medium was replaced. 
Proliferation ability of equine synovial fluid derived stem cells was determined using 
MTT colorimetric assay. A concentration of 1x104cells/well was cultured in a 96-well plate. After 
24 h 20 μl MTT (2 mg/ml, Sigma-Aldrich) was added to each well and cultures were incubated at 
37 °C for 3 h. The fromazan were dissolved with 100 μl DMSO (dimethylsulfoxide, Sigma- 
Aldrich) and the absorbance was measured at 450 nm using a spectrophotometer (Bio-Rad, 
Hercules, CA, USA). In order to evaluate the proliferation rate the population doubling time were 
assessed. A total number of 1x105 cells/ well were seeded in 24-well cell culture plates. After 24 h 
(t24h) the non-adherent and the adherent cells (N0) were counted. 24 h later (t48h) the adherent 
cells from three wells were counted (N48h). The doubling time (tD) was calculated according to 
the formula: tD = (log 2 × t)/ (log N48h - log N0). 
The clonal capacity of cells was evaluated using CFU-F assay. 5x102cells/cm2 was cultured 
in expansion medium. After 10 days the cells were fixed with 4% paraformaldehyde for 10 min 
and stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis, MO) in 10% methanol for 20 
minutes and were examined under phase contrast inverted light microscope (Nikon TS100, Nikon 
Instruments, Europe) and the colonies (> 50 cells) were counted. CFU-F efficiency was estimated 
according to the formula: CFU-F efficiency = (counted CFU-F/cells originally seeded) × 100. 
 
Results and discussion 
MSCs were isolated from harvested from equine tarsometatarsal joint during arthroscopic 
surgery. The isolated cells were characterized to confirm their caracteristics such as plastic 
adherence, expression of specific surface antigens and differentiation potential. Equine synovial 
fluid derived mesenchymal stem cells showed fibroblast-like morphology (fig 1.), adherence to 
plastic surface and express the specific surface markers (CD90, CD105, CD44, results not shown 
here). The proliferation capacities of cells were evaluated using MTT assay. 
 
 
Figura 1. Equine synovial fluid derived cell morphology 
 
The isolated cells lines exhibited similar proliferation potential in evaluated period (d1- 




































Figure 3. Population doubling time in equine synovial fluid derived mesenchymal stem cell lines 
 
Individual assessment at each cell line can be concluded that for line S1 the population 
doubling time was 44±1.01h, 42±5.8 in S2, 38.33±13.86 h in S3, 41.00±3.00 in S4, 41.66±2.08 in 
S5 and 41.66±4.16 in S6 (fig. 3). The average of population-doubling time (PD) was 41.44 ± 1.83 h. 
The clonogenic potential of MSCs was assessed by CFU-F assay. Isolated cells lines displayed 
colony-forming ability; the frequency of colony forming cells for S1 was 37.66±6.42 
colonies/100  cm2,  36.66±6.42  colonies/100  cm2  in  S2,  36.33±7.57  colonies/100cm2   in  S3, 




















Figure 4.The average of colonigenic potential (CFU-F assay) of equine synovial fluid derived 

























Multipotent mesenchymal stem cells (MSCs) represent a promising source of cells for 
regenerative medicine therapeutic approaches in both human and veterinary medicine given their 
properties (Singer et al., 2011, Carrade et al., 2013, Clark et al., 2016, Pall et al., 2016). MSCs can 
be defined by their morphology, expression of a panel of cell surface markers and their tri-lineage 
differentiation (Dominici et al., 2006, Clark et al., 2016). In our study, cells from synovial fluid 
were evaluated as possible sources of MSCs, for equine regenerative medicine. The horse is a 
valuable species for evaluating the usefulness and efficiency of MSC treatment (Pezzanite et al., 
2015). MSCs from different sources are used, but most often autologous bone marrow-derived 
MSCs are used to treat musculoskeletal disorders including tendonitis, osteoarthritis, cartilage 
damage, and meniscal injuries (Schnabel et al., 2009, Frisbie and Smith 2010, Caniglia et al., 2012, 
De Schauwer et al., 2013, Pezzanite et al., 2015). 
MSCs also can modulate endogenous tissue and immune cells (Parekkadan et al., 2010) 
and can migrate to the site of injury after receiving specific signals (Chen et al., 2011). MSCs 
also can be subject  to  cryopreservation  with  minimal  loss  of  potency  (Lee  et  al.,  2005),  
for future heterologous or autologous transplantation. Numerous studies and clinical trials have 




Our study showed that mesenchymal stem cells could be successfully isolated form 
synovial fluid. Characterization of these cells can be achieved based by their morphology, 
immunophenotype and differentiation potential. Results from our study demonstrate the 
proliferative and clonogenic potential of equine synovial fluid derived stem cells, and can serve as 
a potential source of mesenchymal stem cells for veterinary regenerative medicine. 
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